Literature DB >> 2542009

Effect of an osmotic stimulus on the secretion of arginine vasopressin and adrenocorticotropin in the horse.

C H Irvine1, S L Alexander, R A Donald.   

Abstract

Arginine vasopressin (AVP) is released in response to changes in blood osmolality and is also a putative secretagogue for ACTH. However, it is unclear whether osmotically generated increases in AVP in the physiological range influence ACTH secretion. We have studied this question using our unique noninvasive technique for collecting pituitary venous blood in six normal conscious horses that received an iv infusion of hypertonic saline (HS; 5%, 0.07 ml/kg.min) for 45-60 min. Pituitary and jugular venous samples were collected every 5 min for 40 min before, during, and for 20 min after HS. During HS, mean blood osmolality rose (P less than 0.01), with a mean peak increase of 14.8 mosmol/kg (range, +6-+37 mosmol/kg). Jugular AVP rose (P less than 0.01) from 0.56 +/- 0.18 pmol/liter (mean +/- SEM) before HS to 2.16 +/- 0.86 pmol/liter during HS. Mean jugular AVP and osmolality were correlated (r = 0.82; P less than 0.05) during HS. Mean jugular ACTH concentrations increased (P less than 0.01) from 49 +/- 9 ng/liter before HS to 148 +/- 54 ng/liter during HS, while mean cortisol levels during and after HS exceeded basal levels (P less than 0.05). Pituitary AVP and ACTH concentrations exceeded jugular concentrations by up to 100-fold, and mean (P less than 0.01 for both) and peak (P less than 0.001 for both) levels increased during HS. AVP and ACTH secretion during HS were pulsatile. The mean and peak changes in pituitary AVP were significantly correlated with those in ACTH. For the six horses together, pituitary ACTH and AVP concentration changes occurred synchronously during the experiment (P less than 0.001), and the paired AVP and ACTH concentrations were highly correlated (r = 0.73; n = 129 pairs; P less than 0.001). We conclude that 1) physiological changes in AVP secretion are closely associated with comparable changes in ACTH secretion, and 2) osmotic signals that presumably activate the magnocellular neurons of the supraoptic and paraventricular nuclei may be physiologically relevant regulators of corticotrope function.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2542009     DOI: 10.1210/endo-124-6-3102

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

1.  Increase in plasma ACTH induced by urethane is not a consequence of hyperosmolality.

Authors:  Dmitry V Zaretsky; Andrei I Molosh; Maria V Zaretskaia; Daniel E Rusyniak; Joseph A DiMicco
Journal:  Neurosci Lett       Date:  2010-05-12       Impact factor: 3.046

2.  Regulation of Neuronal Activity in Hypothalamic Vasopressin Neurons.

Authors:  Toyoaki Ohbuchi; Juhee Haam; Jeffrey G Tasker
Journal:  Interdiscip Inf Sci       Date:  2015

3.  Angiotensin type 1 receptors in the subfornical organ mediate the drinking and hypothalamic-pituitary-adrenal response to systemic isoproterenol.

Authors:  Eric G Krause; Susan J Melhorn; Jon F Davis; Karen A Scott; Li Y Ma; Annette D de Kloet; Stephen C Benoit; Stephen C Woods; Randall R Sakai
Journal:  Endocrinology       Date:  2008-08-07       Impact factor: 4.736

4.  Vasopressin does not mediate hypersensitivity of the hypothalamic pituitary adrenal axis during chronic stress.

Authors:  Jun Chen; Sharla Young; Sivan Subburaju; Jack Sheppard; Alexander Kiss; Helen Atkinson; Susan Wood; Stafford Lightman; Claudine Serradeil-Le Gal; Greti Aguilera
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

5.  Changes in CRH and ACTH synthesis during experimental and human septic shock.

Authors:  Andrea Polito; Romain Sonneville; Céline Guidoux; Lucinda Barrett; Odile Viltart; Virginie Mattot; Shidasp Siami; Geoffroy Lorin de la Grandmaison; Fabrice Chrétien; Mervyn Singer; Françoise Gray; Djillali Annane; Jean-Philippe Brouland; Tarek Sharshar
Journal:  PLoS One       Date:  2011-11-03       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.